icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Digital Experience
November 13 - 16 - 2020
Back grey_arrow_rt.gif
Cilofexor and Firsocostat in Combination Lead to Greater Reductions in Serum Bile Acids, Which Are Associated With Treatment Response in Patients With Advanced Fibrosis Due to NASH
  AASLD 2020 Nov 11-16
Rohit Loomba,1 Mazen Noureddin,2 Kris V. Kowdley,3 Anita Kohli,4 Aasim Sheikh,5 Bal Raj Bhandari,6 Jen-Chieh Chuang,7 Andrew Billin,7 Scott D. Patterson,7 Lulu Wang,7 Catherine Jia,7 Ryan S. Huss,7 Robert P. Myers,7 Keyur Patel,8 Heidi Kabler,9 Peter Ruane,10 Simone Strasser,11 Vincent Wai-Sun Wong,12 Naim Alkhouri13
1UC San Diego NAFLD Research Center, La Jolla, CA; 2Cedars-Sinai Fatty Liver Program, Los Angeles, CA; 3Liver Institute Northwest and Washington State University, Seattle, WA; 4Arizona Liver Health, Chandler, AZ; 5GI Specialists of Georgia, Marietta; 6Delta Research Partners, LLC, Bastrop, LA; 7Gilead Sciences, Inc., Foster City, CA; 8Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; 9MountainView Hospital, Las Vegas, NV; 10Ruane Medical & Liver Health Institute, Los Angeles; 11Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; 12The Chinese University of Hong Kong, People's Republic of China; 13Texas Liver Institute, UT Health San Antonio, TX







References: 1. Sanyal AJ, et al. EASL 2018, poster FRI-422; 2. Loomba R, et al. EASL 2020, abstr LBO04. 3. Harrison S, et al. AASLD 2017, poster 2122.